Anti-CD19 Reference Antibody (tafasitamab)
Reagent
Code: #139861
blur_circular Chemical Specifications
inventory_2
Storage & Handling
Storage
-20℃
description Product Description
Used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It targets CD19, a protein found on the surface of B-cells, including malignant B-cells. By binding to CD19, it activates immune-mediated cell killing, including antibody-dependent cellular cytotoxicity (ADCC). Often used in combination with lenalidomide to enhance therapeutic effect. Also serves as a reference standard in bioanalytical assays and drug development for evaluating CD19-targeting therapeutics.
format_list_bulleted Product Specification
| Test Parameter | Specification |
|---|---|
| Appearance | Transparent Liquid |
| Purity (SDS-PAGE)(%) | 95-100 |
| Concentration (mg/ml) | Report Result |
| Endotoxin (EU/mg) | 0-1 |
| Mw (kDa) | 147.42 |
| Formulation | Supplied as a 0.22um filtered solution in 100mM Pro-Ac, 20 mM Arg, pH5.0 |
shopping_cart Available Sizes & Pricing
Cart
No products
Subtotal:
0.00
Total
0.00
THB
Loading Researcher Network details...
